Elevation Oncology Inc expected to post a loss of 32 cents a share - Earnings Preview

Elevation Oncology

30/10/2023 18:33

* Elevation Oncology Inc  ELEV.OQ   ELEV.O  is expected
to show no
change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Elevation Oncology
Inc is
for a loss of 32 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Elevation
Oncology Inc is $5​, above​ its last closing price of $0.54. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.26       -0.32      -0.37     Missed  -15
 Mar. 31 2023  -0.62       -0.59      -0.72     Missed  -21.7
 Dec. 31 2022  -0.92       -0.78      -0.82     Missed  -4.9​
 Sep. 30 2022  -1.33       -1.30      -1.67     Missed  -28.7
 ​​Jun.        -0.79       -0.79      -0.86     Missed  -9.2
 30 2022                                                
 Mar. 31 2022  -0.51       -0.50      -0.74     Missed  -46.9​
 Dec. 31 2021  -0.59       -0.59      -0.41     Beat    30
 Sep. 30 2021  -0.36       -0.38      -0.53     Missed  -38.1
 This summary was machine generated October 30 at 18:33 GMT.  All
figures in US dollars  unless otherwise stated